Diagnostic Journey of Korean Patients with Spinal Muscular Atrophy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Spinal muscular atrophy (SMA) is an autosomal recessive genetic disease characterized by the loss of motor neurons in the spinal cord and brainstem, leading to muscle atrophy and weakness. To understand the diagnostic process of Korean patients with SMA, we analyzed their clinical characteristics and challenges. Materials and Methods: We conducted a retrospective study of 38 patients with SMA (9 type II and 29 type III) between January 2000 and September 2023. Clinical, laboratory, and genetic data were reviewed. Results: The median ages at symptom onset and diagnosis were 3.0 years [interquartile range (IQR): 1.0–7.3 years] and 25.0 years (IQR: 10.5–37.3 years), respectively. The median diagnostic delay was 19.6 years (IQR: 6.4–31.0 years). A significantly longer delay was observed in SMA type III patients (median: 21.0 years, IQR: 11.0–31.0 years) compared to SMA type II patients (median: 3.0 years, IQR: 0.9–21.0 years) (p=0.021). No significant difference was observed in the number of clinic visits before diagnosis between patients with SMA type II (median: 2.0, IQR: 1.0–4.5) and those with type III (median: 2.0, IQR: 2.0–6.0, p=0.282). The number of clinic visits before diagnosis showed no significant association with the age at symptom onset and diagnosis (p=0.998 and 0.291, respectively). Conclusion: Our investigation is the first examination of the diagnostic journey of Korean patients with SMA. As treatments for SMA progress, the significance of an accurate diagnosis has increased, highlighting the importance of reviewing the diagnostic advancements made thus far.
Abstract
Purpose: Spinal muscular atrophy (SMA) is an autosomal recessive genetic disease characterized by the loss of motor neurons in the spinal cord and brainstem, leading to muscle atrophy and weakness. To understand the diagnostic process of Korean patients with SMA, we analyzed their clinical characteristics and challenges. Materials and Methods: We conducted a retrospective study of 38 patients with SMA (9 type II and 29 type III) between January 2000 and September 2023. Clinical, laboratory, and genetic data were reviewed. Results: The median ages at symptom onset and diagnosis were 3.0 years [interquartile range (IQR): 1.0–7.3 years] and 25.0 years (IQR: 10.5–37.3 years), respectively. The median diagnostic delay was 19.6 years (IQR: 6.4–31.0 years). A significantly longer delay was observed in SMA type III patients (median: 21.0 years, IQR: 11.0–31.0 years) compared to SMA type II patients (median: 3.0 years, IQR: 0.9–21.0 years) (p=0.021). No significant difference was observed in the number of clinic visits before diagnosis between patients with SMA type II (median: 2.0, IQR: 1.0–4.5) and those with type III (median: 2.0, IQR: 2.0–6.0, p=0.282). The number of clinic visits before diagnosis showed no significant association with the age at symptom onset and diagnosis (p=0.998 and 0.291, respectively). Conclusion: Our investigation is the first examination of the diagnostic journey of Korean patients with SMA. As treatments for SMA progress, the significance of an accurate diagnosis has increased, highlighting the importance of reviewing the diagnostic advancements made thus far.
참고문헌 (20)
- Pera MC, "Diagnostic journey in spinal muscular atrophy : is it still an odyssey?", PLoS One, 15, pp.e0230677~ (2020)
- D’Amico A, "Spinal muscular atrophy", Orphanet J Rare Dis, 6, pp.71~ (2011)
- Melki J, "De novo and inherited deletions of the 5q13 region in spinal muscular atrophies", Science, 264, pp.1474~1477 (1994)
- Crawford TO, "Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy(BforSMA)clinical study", PLoS One, 7, pp.e33572~ (2012)
- Mercuri E, "Spinal muscular atrophy—insights and challenges in the treatment era", Nat Rev Neurol, 16, pp.706~715 (2020)
- Pearn J, "Classification of spinal muscular atrophies", Lancet, 1, pp.919~922 (1980)
- Finkel RS, "Nusinersen versus sham control in infantile-onset spinal muscular atrophy", N Engl J Med, 377, pp.1723~1732 (2017)
- Mercuri E, "Nusinersen versus sham control in later-onset spinal muscular atrophy", N Engl J Med, 378, pp.625~635 (2018)
- Carter M, "Room to improve : the diagnostic journey of spinal muscular atrophy", Eur J Paediatr Neurol, 42, pp.42~46 (2023)
- Li Q, "Nusinersen as a therapeutic agent for spinal muscular atrophy", Yonsei Med J, 61, pp.273~283 (2020)
- Hwang H, "Clinical characteristics of spinal muscular atrophy in Korea confirmed by genetic analysis", Yonsei Med J, 58, pp.1051~1054 (2017)
- Lin CW, "Delay in diagnosis of spinal muscular atrophy : a systematic literature review", Pediatr Neurol, 53, pp.293~300 (2015)
- Diaz CB, "Diagnostic journey of patients with spinal muscular atrophy in Argentina", J Neurol Sci, 429, pp.118427~ (2021)
- Farrar MA, "Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy", J Pediatr, 162, pp.155~159 (2013)
- Mercuri E, "Spinal muscular atrophy", Nat Rev Dis Primers, 8, pp.52~ (2022)
- Calucho M, "Correlation between SMA type and SMN2 copy number revisited : an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases", Neuromuscul Disord, 28, pp.208~215 (2018)
- Lawton S, "A mixed methods exploration of families’ experiences of the diagnosis of childhood spinal muscular atrophy", Eur J Hum Genet, 23, pp.575~580 (2015)
- Qian Y, "Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents : a qualitative study", BMC Neurol, 15, pp.217~ (2015)
- Buchthal F, "Electromyography and muscle biopsy in infantile spinal muscular atrophy", Brain, 93, pp.15~30 (1970)
- Arnold WD, "Spinal muscular atrophy : diagnosis and management in a new therapeutic era", Muscle Nerve, 51, pp.157~167 (2015)